Business Practice

IFPMA’s Director-General, Thomas Cueni, outlines how companies worldwide can foster long-term tech transfer partnerships.

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

It’s time for pharma companies to embrace digital technologies.

We talk to Roche’s Paulo Fontoura about Evrysdi and its impact on patient lives.

In this new series, we ask industry leaders in the cell and gene field to answer key questions about the industry.

2022 is well underway, and with it comes The Medicine Maker Company of the Year Awards. Our old faithful Power List is back too.

How will the pharmaceutical landscape shape up in 2022? Industry experts share their predictions.

COVID-19 caused a shift in scientific research. But what happened to the research programs that existed before the pandemic hit?

The pharmaceutical industry experienced its fair share of challenges and success in 2021. We break down the sector's biggest moments here.

We interview Vetter’s Thomas Otto about his career and the importance of sustainability in the pharma industry.